Galmed Pharmaceutica (GLMD)

$0.83 -0.02 (-1.99%)
Market Cap 1.38M
Revenue (ttm) 0.00
Net Income (ttm) -7.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,900
Avg Vol 2,584,100
Day's Range N/A - N/A
Shares Out 1.65M
Stochastic %K 68%
Beta 0.35
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
Buyer52WeeksLow
Buyer52WeeksLow Jan. 12 at 1:16 AM
$GLMD sell it $6
1 · Reply
Buyer52WeeksLow
Buyer52WeeksLow Jan. 12 at 1:16 AM
$GLMD hold for $6
0 · Reply
madan_shatri
madan_shatri Jan. 10 at 6:18 AM
$GLMD has anyone gone through complete details of GLMD pipeline mentioned on their website ?
1 · Reply
madan_shatri
madan_shatri Jan. 9 at 9:03 PM
$GLMD So whole week from Monday to Friday, we closed at 1% gain By the way day 18 under $1.00
1 · Reply
Lowlyme
Lowlyme Jan. 8 at 11:38 PM
$GLMD lOL thanks.
0 · Reply
madan_shatri
madan_shatri Jan. 8 at 6:47 PM
$GLMD Day 17 under $1.00
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 8 at 5:13 PM
$GLMD they do own the patent and this is worth something.
1 · Reply
Lowlyme
Lowlyme Jan. 8 at 4:58 PM
$GLMD Risky? Really? What could possibly be risky about a stock that has been in non-compliance 3 o4 times in the past couple of years. And gone through how many? 3 reverse splits? And hasn't been above a zero on a 5 year chart since 2023? Mystery to me how Schwab could find that risky. But they're the experts I guess.
0 · Reply
IncredibleGuy
IncredibleGuy Jan. 8 at 2:57 PM
$GLMD Schwab not letting me buy this. anyone else having same issue ?
2 · Reply
Morpomex
Morpomex Jan. 7 at 11:02 PM
$GLMD Let’s go!
0 · Reply
Latest News on GLMD
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 4 weeks ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 5 weeks ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 5 weeks ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 6 weeks ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 7 weeks ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 7 weeks ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 4 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 8 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 8 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 8 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 9 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 9 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 9 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 10 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 10 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 22, 2023, 4:05 PM EDT - 2 years ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 1:56 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed announces positive results of Phase 1 study of Amilo-5MER

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Buyer52WeeksLow
Buyer52WeeksLow Jan. 12 at 1:16 AM
$GLMD sell it $6
1 · Reply
Buyer52WeeksLow
Buyer52WeeksLow Jan. 12 at 1:16 AM
$GLMD hold for $6
0 · Reply
madan_shatri
madan_shatri Jan. 10 at 6:18 AM
$GLMD has anyone gone through complete details of GLMD pipeline mentioned on their website ?
1 · Reply
madan_shatri
madan_shatri Jan. 9 at 9:03 PM
$GLMD So whole week from Monday to Friday, we closed at 1% gain By the way day 18 under $1.00
1 · Reply
Lowlyme
Lowlyme Jan. 8 at 11:38 PM
$GLMD lOL thanks.
0 · Reply
madan_shatri
madan_shatri Jan. 8 at 6:47 PM
$GLMD Day 17 under $1.00
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 8 at 5:13 PM
$GLMD they do own the patent and this is worth something.
1 · Reply
Lowlyme
Lowlyme Jan. 8 at 4:58 PM
$GLMD Risky? Really? What could possibly be risky about a stock that has been in non-compliance 3 o4 times in the past couple of years. And gone through how many? 3 reverse splits? And hasn't been above a zero on a 5 year chart since 2023? Mystery to me how Schwab could find that risky. But they're the experts I guess.
0 · Reply
IncredibleGuy
IncredibleGuy Jan. 8 at 2:57 PM
$GLMD Schwab not letting me buy this. anyone else having same issue ?
2 · Reply
Morpomex
Morpomex Jan. 7 at 11:02 PM
$GLMD Let’s go!
0 · Reply
getsometoday
getsometoday Jan. 7 at 9:21 PM
$GLMD we are a little overdue for a p r.
0 · Reply
madan_shatri
madan_shatri Jan. 6 at 4:30 PM
$GLMD Today is Day 15 under $1.00 and Jan 27 will be the 30th day in case it continues to trade under $1.00 and in case there is no holiday in between
0 · Reply
johnny6nine
johnny6nine Jan. 6 at 4:15 PM
$GLMD holding a pretty decent size loss, but will continue to average down for a long as it takes!!
0 · Reply
VolcanicTrades
VolcanicTrades Jan. 5 at 10:46 PM
$GLMD this is undervalued. I just hope they run it past 1.70s this time. Above average volume. No news. High watch for 📰
0 · Reply
funnymoney90210
funnymoney90210 Jan. 5 at 6:56 PM
$GLMD scam! The brokers wont let you buy unless you call
2 · Reply
getsometoday
getsometoday Jan. 5 at 4:24 PM
$GLMD I fully expect more PRs at a pace we saw last quarter in light of the letter to s/h. The management knows it will be a challenging time for price action. But they will remain budget disciplined on the burn rate. Be patient.
1 · Reply
Lowlyme
Lowlyme Jan. 5 at 2:01 AM
$GLMD Make that the last quarter century.
0 · Reply
Lowlyme
Lowlyme Jan. 5 at 2:00 AM
$GLMD Or Onkai. Or Crypto. Etc. Etc. The only thing consistent here is the CEO's salary for the last five years.
0 · Reply
never_chase
never_chase Jan. 2 at 7:02 PM
$GLMD any news here ?
0 · Reply
getsometoday
getsometoday Jan. 1 at 10:22 PM
$GLMD I don’t think a development stage bio is by definition in a position to buy back shares. If there is any truth to the combination studies then they will have Bayers attention and it will just get bought while it’s cheap at a price consistent with PV of the market benefit. The patent protection will force the issue unless they sign over the rights to Bayer and then fold that capital back into other uses for Aramchol such as MASH.
1 · Reply
MSG8898
MSG8898 Jan. 1 at 2:03 PM
$GLMD Madan, I am on your side. IMO anytime a CEO feels the need to write a letter to shareholders, there's IMO something wrong. They should let actions speak. I see as a huge negative the 2M UK investment, to me it just doesn't make any sense. That money would have been so beneficial to shareholders if it was used to buy back shares. The fact that they decided to use it otherwise, means something to me, and it's not pretty, IMO. I agree that IMO this has what I call an endless ATM in place to keep things going, regardless of the share price.
2 · Reply
Lowlyme
Lowlyme Dec. 31 at 11:40 PM
$GLMD Go Allen.
0 · Reply